Do Not Mail List & Western Pharmaceutical Companies In China

My friend Per Terje inspired me to look for this, and I was happy to find it does exist! Reduce the amount of junk mail that comes to you! Register your address here, though for some of these, they ask payment:

https://www.directmail.com/directory/mail_preference/
https://www.optoutprescreen.com/opt_form.cgi
http://www.41pounds.org/

This one stops catalog mailings:
http://www.catalogchoice.org/

Here's a link to send Congress a message requesting a government sponsored "Do Not Mail List", but who knows how effective these things actually are:
http://www.democracyinaction.org/dia/organizationsORG/newdream/campaign.jsp?campaign_KEY=5076&t=default.dwt

Also, here's an interesting article:

Western drugs sell slowly in herb-happy China

Colleen Cheng and Angel Chen, Chinese marketing executives in their 30s, should be the ideal customers for U.S. and European drugmakers. So far, they are a tough sell. Glued to cell phones at an expensive Beijing restaurant, the working moms would fit in at any cafe in New York or London with their fluent English and stylish clothing. They spend hundreds of dollars monthly on herbs, acupuncture and supplements. What they don’t buy are Western pharmaceuticals, like Johnson & Johnson’s cold medicine Sudafed and Sanofi-Aventis SA’s sleeping pill Ambien.


“With Chinese medicine, it is all about balance,” Cheng says. For a cold, she boils ginger root in Coca-Cola. Rather than take a sleeping pill, Chen drinks Chinese white wine. “The effect of the Chinese medicine is very slow, but we continue to take it because we believe it is better for our overall health,” Cheng says. While China’s middle class has fallen for Buick cars and Starbucks coffee, medicines made by Western drugmakers haven’t caught on as quickly. The average Chinese spends $10 a year on pharmaceuticals compared with $900 for each American. The world’s biggest drugmakers, including Pfizer Inc., Johnson & Johnson and GlaxoSmithKline Plc, need to court customers like Cheng and Chen as sales growth slows in the mature U.S. and European markets.

Read more at: http://www.telegram.com/article/20071230/NEWS/712300333/1002/BUSINESS